Richmond, Canada
Virogin Biotech, founded in 2015, is headquartered in Canada and operates within the Biotechnology and Health Care industries. The company's slogan, "Virotherapy to Ignite Immunotherapy," reflects its strategic focus on developing pioneering oncolytic virus therapies designed to trigger robust antitumor immune responses in patients.
Leveraging over 25 years of collective expertise in immunotherapy and oncolytic virotherapy, Virogin Biotech is committed to advancing treatments for relapsed and refractory cancer types. Its platform technology aims to synthesize potent oncolytic viruses that express optimized payloads, potentially enhancing systemic antitumor immunity.
The company last secured a Series D investment on 24 September 2021. Investors interested in ground-breaking advancements in oncolytic virotherapy should consider Virogin Biotech as a potential contender poised to make significant impacts within the realm of cancer treatment therapies.
